Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 646 AL 660

Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine

Kovacs GG.

Int J Mol Sci. 2016 Feb 2;17(2):189. doi: 10.3390/ijms17020189.

The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease

Perez-Lloret S, Rascol O.

Expert Rev Neurother. 2016;16(3):245-58. doi: 10.1586/14737175.2016.1150783. Epub 2016 Feb 19.

Computational Study and Modified Design of Selective Dopamine D3 Receptor Agonists

Duan X, Zhang X, Xu B, Wang F, Lei M.

Chem Biol Drug Des. 2016 Jul;88(1):142-54. doi: 10.1111/cbdd.12743. Epub 2016 Mar 9.

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Athauda D, Foltynie T.

Drug Discov Today. 2016 May;21(5):802-18. doi: 10.1016/j.drudis.2016.01.013. Epub 2016 Feb 3.

MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study

Biundo R, Weis L, Bostantjopoulou S, Stefanova E, Falup-Pecurariu C, Kramberger MG, Geurtsen GJ, Antonini A, Weintraub D, Aarsland D.

J Neural Transm (Vienna). 2016 Apr;123(4):431-8. doi: 10.1007/s00702-016-1517-6. Epub 2016 Feb 6.

The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease

Benskey MJ, Perez RG, Manfredsson FP.

J Neurochem. 2016 May;137(3):331-59. doi: 10.1111/jnc.13570. Epub 2016 Mar 23.

A cumulative genetic risk score predicts progression in Parkinson's disease

Pihlstrøm L, Morset KR, Grimstad E, Vitelli V, Toft M.

Mov Disord. 2016 Apr;31(4):487-90. doi: 10.1002/mds.26505. Epub 2016 Feb 8.

Can the silkworm (Bombyx mori) be used as a human disease model?

Tabunoki H, Bono H, Ito K, Yokoyama T.

Drug Discov Ther. 2016 Feb;10(1):3-8. doi: 10.5582/ddt.2016.01011. Epub 2016 Feb 7.

Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study

Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG, Marras C, Juncos J, Riley D, Reich S, Hall D, Kluger B, Bordelon Y, Shprecher DR; for ENGENE-PSP.

Mov Disord. 2016 May;31(5):644-52. doi: 10.1002/mds.26512. Epub 2016 Feb 8.

Neurocognitive & neuropsychiatric phenotypes of PARK2-associated early-onset Parkinson's disease in two siblings

Anderson-Mooney AJ, Guller L, Combs HL, Dunham KJ.

Clin Neurol Neurosurg. 2016 Mar;142:137-139. doi: 10.1016/j.clineuro.2016.01.016. Epub 2016 Feb 1.

The safety of treatments for prolactinomas

Auriemma RS, Grasso LF, Pivonello R, Colao A.

Expert Opin Drug Saf. 2016;15(4):503-12. doi: 10.1517/14740338.2016.1151493. Epub 2016 Mar 7.

Of Pesticides and Men: a California Story of Genes and Environment in Parkinson's Disease

Ritz BR, Paul KC, Bronstein JM.

Curr Environ Health Rep. 2016 Mar;3(1):40-52. doi: 10.1007/s40572-016-0083-2.

Neuroteratology and Animal Modeling of Brain Disorders

Archer T, Kostrzewa RM.

Curr Top Behav Neurosci. 2016;29:1-40. doi: 10.1007/7854_2015_434.

Myeloid Extracellular Vesicles: Messengers from the Demented Brain

Nigro A, Colombo F, Casella G, Finardi A, Verderio C, Furlan R.

Front Immunol. 2016 Jan 29;7:17. doi: 10.3389/fimmu.2016.00017. eCollection 2016.

Double homozygous mutations (R275W and M432V) in the ParkinGene associated with late-onset Parkinson's disease

Carr J, Guella I, Szu-Tu C, Boolay S, Glanzmann B, Farrer MJ, Bardien S.

Mov Disord. 2016 Mar;31(3):423-5. doi: 10.1002/mds.26524. Epub 2016 Feb 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias